Caterpillar’s potential 2021 benefits and enhanced efficacy of AstraZeneca vaccine
With COVID vaccines distributed nationwide and the S & P 500 remaining nearly green for the past few months, some investors have identified it as a stock that moves in tandem with economic recovery, most commonly as a “circulating stock.” is known. One of these investments is Caterpillar, a construction giant and one of the world’s largest machinery manufacturers.
Caterpillar sales have recently bottomed out and the economy is expected to resume in 2021, with many investors expecting Caterpillar to turn positive. This potential cash flow is especially beneficial to many, as Caterpillar has prioritized investor dividends in the past. Despite this, many denials believe that this recovery may be weaker than other recovery, but it is a unique situation and many of the rebounds are already priced by investor speculation. I am.
Pascal Soriot, CEO of AstraZeneca, has revealed new data showing that their vaccine is as effective as Moderna and Pfizer and can protect about 95% of patients. This is a big boost from previous assessments that left the vaccine on the competition, with an average efficacy of 70%.
This may look like another player added to the stalemate, but the AstraZeneca vaccine is considered easier and cheaper than the Pfizer and Moderna vaccines, which is especially beneficial for developing countries. .. The good news reveals that FDA approval will take time, and vaccine distribution supply chains and logistics will be complex and time consuming, with some delays.
I am not a financial adviser. My comments should not be taken as financial advice. There are risks associated with investing, so be sure to conduct a survey and analysis in advance.
Caterpillar’s potential 2021 benefits and enhanced efficacy of AstraZeneca vaccine 💉
https://invstr.com/29-december-watchlist-2/ Caterpillar’s potential 2021 benefits and enhanced efficacy of AstraZeneca vaccine 💉